- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AHIP Statement on the Administration’s National Effort Calling for COVID-19 Survivors to Donate Plasma
Coronavirus disease 2019 (COVID-19) has presented new challenges every day, as well as new opportunities.
WASHINGTON, D.C. – Matt Eyles, president and CEO of America’s Health Insurance Plans (AHIP), issued this statement following the Administration’s announcement of a nationwide effort to encourage everyone who has recovered from coronavirus disease 2019 (COVID-19) and has been symptom-free for at least 14 days to donate plasma. This plasma will be used to help other patients recover from COVID-19.
“Since COVID-19 first impacted our nation, we’ve seen ‘ordinary’ Americans do extraordinary things. Seemingly overnight, our country’s doctors, nurses, hospital personnel, emergency medical services workers, and public health leaders transformed into heroes, putting the health of the patients and communities they serve ahead of their own and in spite of very serious risks to themselves and their families. Our truckers, grocers, and manufacturers are working overtime to keep America supplied and fed. Health insurance providers are working with partners across our communities to ensure access to much-needed care and services. And millions of Americans are checking on friends, neighbors, and loved ones to offer support or a helping hand."
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
